OBI-201 / OBI Pharma - LARVOL DELTA

Obi‑201: a bispecific trop2 × her2 antibody-drug conjugate to expand therapeutic reach beyond her2-low limitations (SABCS 2025) - "OBI‑201 demonstrated superior antitumor activity compared to Enhertu®, Datroway®, and Trodelvy® in HER2-low colorectal, pancreatic, and NSCLC models, as well as in Enhertu-resistant NSCLC CDX models. OBI-201 is a next-generation bispecific ADC targeting HER2 and TROP2, designed to overcome the limitations of single-target therapies. Its dual-targeting approach, enabled by GlycOBI®, proprietary ADC enabling technologies for precise payload delivery, offers strong potential to overcome HER2-low expression and resistance, addressing significant unmet needs across a broad spectrum of solid tumors."

Breast Cancer • Triple Negative Breast Cancer • TACSTD2